KR20240035394A - 안질환 치료를 위한 성장 인자 조성물 - Google Patents

안질환 치료를 위한 성장 인자 조성물 Download PDF

Info

Publication number
KR20240035394A
KR20240035394A KR1020237042977A KR20237042977A KR20240035394A KR 20240035394 A KR20240035394 A KR 20240035394A KR 1020237042977 A KR1020237042977 A KR 1020237042977A KR 20237042977 A KR20237042977 A KR 20237042977A KR 20240035394 A KR20240035394 A KR 20240035394A
Authority
KR
South Korea
Prior art keywords
gly
amino acids
seq
leu
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237042977A
Other languages
English (en)
Korean (ko)
Inventor
피오트르 브릴라
수잔 씨. 오르
에이. 클라크 아트웰
Original Assignee
클라리스 바이오쎄라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 클라리스 바이오쎄라퓨틱스, 인코포레이티드 filed Critical 클라리스 바이오쎄라퓨틱스, 인코포레이티드
Publication of KR20240035394A publication Critical patent/KR20240035394A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
KR1020237042977A 2021-05-14 2022-05-13 안질환 치료를 위한 성장 인자 조성물 Pending KR20240035394A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163188816P 2021-05-14 2021-05-14
US63/188,816 2021-05-14
PCT/US2022/072302 WO2022241465A1 (en) 2021-05-14 2022-05-13 Compositions of growth factor for the treatment of eye disease

Publications (1)

Publication Number Publication Date
KR20240035394A true KR20240035394A (ko) 2024-03-15

Family

ID=81756753

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237042977A Pending KR20240035394A (ko) 2021-05-14 2022-05-13 안질환 치료를 위한 성장 인자 조성물

Country Status (12)

Country Link
US (1) US20230022990A1 (cg-RX-API-DMAC7.html)
EP (2) EP4337243A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024518178A (cg-RX-API-DMAC7.html)
KR (1) KR20240035394A (cg-RX-API-DMAC7.html)
CN (1) CN117677394A (cg-RX-API-DMAC7.html)
AU (1) AU2022272740A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023022474A2 (cg-RX-API-DMAC7.html)
CA (1) CA3218000A1 (cg-RX-API-DMAC7.html)
IL (1) IL308496A (cg-RX-API-DMAC7.html)
MX (1) MX2023012782A (cg-RX-API-DMAC7.html)
TW (1) TW202310868A (cg-RX-API-DMAC7.html)
WO (1) WO2022241465A1 (cg-RX-API-DMAC7.html)

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3486459D1 (de) 1983-09-26 1997-12-11 Udo Dr Med Ehrenfeld Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US5510329A (en) * 1988-04-26 1996-04-23 Ramot University For Applied Research And Industrial Development Ltd. Preparations for the treatment of eyes
NZ232813A (en) 1989-03-10 1992-08-26 Snow Brand Milk Products Co Ltd Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons
JP3927248B2 (ja) 1995-07-11 2007-06-06 第一製薬株式会社 Hgf凍結乾燥製剤
JP4006058B2 (ja) * 1997-03-11 2007-11-14 第一三共株式会社 多臓器不全予防及び/又は治療剤
CA2375779A1 (en) * 1999-05-31 2000-12-07 Mitsubishi Chemical Corporation Lyophilized hgf preparation
JP2000344680A (ja) * 1999-05-31 2000-12-12 Mitsubishi Chemicals Corp Hgf含有医薬組成物
WO2004026244A2 (en) * 2002-09-18 2004-04-01 Emiliano Ghinelli Use of a human amniotic membrane composition for prophylaxis and treatment of diseases and conditions of the eye and skin
JP5093783B2 (ja) * 2006-04-20 2012-12-12 クリングルファーマ株式会社 Hgf前駆体蛋白質改変体及びその活性型蛋白質
WO2008102452A1 (ja) 2007-02-22 2008-08-28 Kringle Pharma Inc. Hgf製剤
US8895508B2 (en) * 2009-07-24 2014-11-25 Yasuhiki Tabata Methods for corneal endothelial proliferation using bFGF sustained-release gelatin hydrogel particles
KR102291913B1 (ko) * 2014-04-28 2021-08-23 에자이 알앤드디 매니지먼트 가부시키가이샤 Hgf의 동결건조 제제
DK3192524T3 (da) 2014-09-10 2022-02-14 Kringle Pharma Inc Hgf præparat egnet til behandling af neurologiske lidelser
JP6929273B2 (ja) * 2015-09-11 2021-09-01 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド 角膜の混濁および瘢痕化の予防および治療のための組成物および方法
US11479591B2 (en) * 2017-05-05 2022-10-25 Trefoil Therapeutics, Inc. Recombinant modified fibroblast growth factors and therapeutic uses thereof
CN116710568A (zh) * 2020-06-26 2023-09-05 特里福伊尔治疗公司 重组修饰成纤维细胞生长因子及其治疗用途

Also Published As

Publication number Publication date
IL308496A (en) 2024-01-01
CN117677394A (zh) 2024-03-08
US20230022990A1 (en) 2023-01-26
AU2022272740A9 (en) 2023-11-09
JP2024518178A (ja) 2024-04-25
BR112023022474A2 (pt) 2024-01-09
WO2022241465A1 (en) 2022-11-17
TW202310868A (zh) 2023-03-16
CA3218000A1 (en) 2022-11-17
EP4574211A2 (en) 2025-06-25
MX2023012782A (es) 2024-03-25
EP4574211A3 (en) 2025-09-10
EP4337243A1 (en) 2024-03-20
AU2022272740A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
Klenkler et al. Growth factors in the tear film: role in tissue maintenance, wound healing, and ocular pathology
US6238888B1 (en) Keratinocyte growth factor-2 formulations
US20120315256A1 (en) Use of transforming growth factor - beta 1 (tgf-b1) inhibitor peptides for the treatment of corneal fibrosis and/or haze
CN102655877B (zh) Fgf21突变体及其用途
Abdelkader et al. New therapeutic approaches in the treatment of diabetic keratopathy: a review
Wang et al. A thermo-responsive protein treatment for dry eyes
US20060287234A1 (en) Wound healing
CA2375829A1 (en) Keratinocyte growth factor-2 formulations
EP4031117B1 (en) Ngf mutant for use in treatment or prevention of ophthalmic disorders
CN111148755A (zh) 重组经修饰成纤维细胞生长因子及其治疗用途
Jiang et al. Pharmacology study of a chimeric decoy receptor trap fusion protein on retina neovascularization by dual blockage of VEGF and FGF-2
US8518412B2 (en) Partial peptide of lacritin
US6869927B1 (en) Keratinocyte growth factor-2 formulations
US20230022990A1 (en) Compositions of growth factor for the treatment of eye disease
US20250002557A1 (en) Multi-specific ligand-binding molecules and applications thereof
HK40128523A (en) Compositions of growth factor for the treatment of eye disease
US8207119B2 (en) Ophthalmological composition
CA3147828C (en) Agent for use in treatment or prevention of ophthalmic disorders
MXPA00006154A (en) Keratinocyte growth factor-2 formulations

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231212

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250513

Comment text: Request for Examination of Application